Clinical Research Programs at Pacific Shores Medical Group
Click on diagnosis for more information or Call Irene at 562-590-0345 Ext. 266
| ANEMIA | |
| BONE METASTASES* | |
| BREAST CANCER | |
| prevention adjuvant metastatic 1st line metastatic 2nd/3rd line |
|
| COLON AND RECTAL CANCER | |
| adjuvant metastatic 1st line metastatic 2nd/3rd line |
|
| KIDNEY | |
| LUNG | |
| LYMPHOMA | |
| MELANOMA | |
| PANCREAS | |
| PROSTATE | |
| SOLID TUMORS | |
| * Metastatic | Cancer resulting from the spread of the primary tumor |
| **Adjuvant therapy | Anticancer drugs, hormones, radiation therapy or other medication given after surgery to prevent the cancer from coming back |
A Randomized, Open-Label, Comparative Study Of Epoetin Alfa (PROCRIT®) 80,000 Units or 120,000 Units Every Q3W Versus Darbepoetin Alfa (ARANESP®) 500 mcg Q3W In Anemic Cancer Subjects Receiving Chemotherapy |
|
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response |
|
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment with Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab, in Patients with Stage II or Stage Ill Breast Cancer |
|
A Phase II, Open-Label, Multicenter, Pilot Study of the Safety and Efficacy of Two Docetaxel Based Regimens plus Bevacizumab for the Adjuvant Treatment of Patients with Node Positive or High Risk Node Negative Breast Cancer (on Hold) |
|
| NSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients completing Five years of Hormonal therapy consisting of an Aromatase inhibitor (AI) or Tamoxifen followed by an Al in prolonging Disease-Free survival in Postmenopausal Women with Hormone Receptor positive Breast Cancer | |
NSABP B-36: A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC) in Patients With Node-Negative Breast Cancer |
|
| A Phase II, Open-Label, Randomized, Multicenter trial of GW786034 (Pazopanib) in Combination with Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects with Advanced or Metastatic Breast Cancer with ErbB2 Fluorescence In Situ Hybridization (FISH) Positive Tumors | |
Phase II Randomized Trial of Faslodex® and Herceptin®, Alone and Combined, in the First-Line treatment of Hormone Receptor-Positive, HER-2/neu-Overexpressing Metastatic Breast Cancer |
|
| Back to Top | A Multicenter, Phase III, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination With Chemotherapy Regimens In Subjects With Previously Treated Metastatic Breast Cancer |
A Phase II Trial To Evaluate The Efficacy And Safety Of Bevacizumab In Combination With Capecitabine (Xeloda) In Frail Patients With Untreated Metastatic Colorectal Cancer |
|
A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with Either Panitumumab or Bevacizumab as Second-line Treatment in Subjects with Metastatic Colorectal Cancer (SPIRITT (“Second-Line Panitumumab-IRlnotecan Treatment Trial”)) |
|
| A single arm, multicenter phase II study of RAD001 in patients with metastatic colorectal adenocarcinoma whose cancer has progressed despite prior therapy with an anti-EGFR antibody (if appropriate), bevacizumab, fluoropyrimidine, oxaliplatin, and irinotecan-based regimens | |
An Open-Label Randomized Phase III Study of Dasatinib vs. Standard-Dose (400 mg) Imatinib Mesylate in the Treatment of Subjects with Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia who have had a Suboptimal Response after 3-12 months of Therapy with 400 mg Imatinib |
|
SMALL CELL |
A Randomized Phase 3 Trial of ALIMTA® (Pemetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer |
SMALL CELL |
A Phase 2, Multicenter, Open Label, Randomized Trial of AMG 706 or Bevacizumab in Combination With Paclitaxel and Carboplatin for Advanced Non-squamous Non-small Cell Lung Cancer |
NON SMALL CELL |
A Randomized, Phase Ill Trial of ABI-007 and Carboplatin® Compared with Taxol® and Carboplatin® as First-line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) |
NON SMALL CELL |
OSI-774-203 A Phase 2 Randomized Study of Tarceva® (Erlotinib) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer who have Tumors with EGFR Protein Overexpression and/or Increased EGFR Gene Copy Numbers |
NON SMALL CELL |
Phase II Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second-Line Treatment in Patients with Non-Small Cell Lung Cancer |
| A Phase III, Randomized, Double-Blinded, Multi-Center Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination with ZD6474 (ZACTIMA™) versus Docetaxel (TAXOTERET™) in combination with Placebo in Patients With Locally Advanced or Metastatic (Stage IIIb-IV) Non-small Cell Lung Cancer (NSCLC) after Failure of 1st Line Anti-Cancer Therapy | |
| A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin | |
| A Randomized, Open-Label, Multicenter Study of VELCADE with Rituximab or Rituximab Alone in Subjects with Relapsed or Refractory, Rituximab Naïve or Sensitive Follicular B-cell Non Hodgkin’s Lymphoma | |
| Back to Top | |
| MULTIPLE MYELOMA | |
| PANCREAS | |
| PREVENTION | |
| PROSTATE | |
| A Phase II Trial of Adjuvant Bevacizumab and Erlonitib in Patients at High Risk for Early Relapse following Radical Prostatectomy for Prostate Cancer | |
| A Randomized Double-blind, Placebo Controlled Study of the Effects of Pomegrate Extract on Rising Prostate-Specific Antigen Levels in Men following Primary Therapy for Prostate Cancer | |
| A Randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer Denosumab | |
| SOLID TUMOR | |
| A Phase Ib, Multi-Center, Open Label, Dose Escalation Trial of Intravenous PR-104 Given in Combination with Docetaxel or Gemcitabine in Subjects with Solid Tumors | |
| An Open-label Treatment Extension Study of AMG 706 | |
| * Metastatic | Cancer resulting from the spread of the primary tumor |
| **Adjuvant therapy | Anticancer drugs, hormones, radiation therapy or other medication given after surgery to prevent the cancer from coming back |